AVXL

Anavex Life Sciences Corp.

2.63 USD

Last updated Sep 14, 05:26 UTC

Yesterday HIGH

$2.74

Yesterday LOW

$2.61

52w HIGH

$10.4

52w LOW

$2.26

EPS

0.08

PE

32.88

Next Earnings

Nov 24, 2026

Overview News Government Trades Fundamentals

Anavex Life Sciences Corp. stock is down -18.32% since 30 days ago. The next earnings date is Nov 24, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 September’s closed higher than August.

Benzinga Newsdesk

Wed Sep 2, 2026

Anavex Life Sciences Regains Nasdaq Compliance

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS")
Benzinga Newsdesk

Tue Aug 25, 2026

Anavex Life Sciences shares are trading higher after the company reported better-than-expected Q3 EPS results.
Benzinga Newsdesk

Tue Aug 25, 2026

Anavex Life Sciences Q3 EPS $0.08 Beats $(0.08) Estimate

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.08) by 200 percent. This is a 150 percent increase over losses of $(0.16) per share from
Benzinga Newsdesk

Mon Aug 3, 2026

Anavex Life Sciences Urges Stockholders To Reject Attempt By PVG Asset Management And Patrick S. Adams To Acquire Control Of The Company

Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life SciencesMr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with
Benzinga Newsdesk

Thu Jul 30, 2026

Anavex Life Sciences Q2 EPS $(0.06) Beats $(0.08) Estimate

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 53.85 percent increase over losses of $(0.13) per share
Benzinga Newsdesk

Thu Jul 30, 2026

Anavex Life Sciences Reports Preliminary Q2 Net Loss Of $0.06 Per Share vs. $0.13 A Year Ago; $127.4M Cash Funds Operations Into Mid-To-Late Fiscal 2028
Benzinga Newsdesk

Fri May 22, 2026

Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it
Benzinga Newsdesk

Wed May 6, 2026

Anavex Names Former Clinical Development Head Kellmeyer As Interim CEO After Board Requests Missling's Resignation
Benzinga Newsdesk

Tue Apr 14, 2026

Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder And Alzheimer's Disease

Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.Epidemiological data show that autistic adults